These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 35139693)

  • 21. Development of refractive error in individual children with regressed retinopathy of prematurity.
    Wang J; Ren X; Shen L; Yanni SE; Leffler JN; Birch EE
    Invest Ophthalmol Vis Sci; 2013 Sep; 54(9):6018-24. PubMed ID: 23920368
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Risk factors for myopia at 1-year corrected age following laser photocoagulation for retinopathy of prematurity.
    Mori Y; Arima M; Ueda E; Fujiwara K; Seki E; Nakama T; Tsukamoto S; Akiyama M; Sonoda KH
    Eye (Lond); 2021 Oct; 35(10):2820-2825. PubMed ID: 33257802
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Refractive outcomes comparing primary laser to primary bevacizumab with delayed laser for type 1 ROP.
    Anand N; Blair MP; Greenwald MJ; Rodriguez SH
    J AAPOS; 2019 Apr; 23(2):88.e1-88.e6. PubMed ID: 30797978
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combined intravitreal ranibizumab and zone I sparing laser ablation in infants with posterior zone I retinopathy of prematurity.
    Parchand SM; Agrawal D; Gangwe A; Saraogi T; Agrawal D
    Indian J Ophthalmol; 2021 Aug; 69(8):2164-2170. PubMed ID: 34304202
    [TBL] [Abstract][Full Text] [Related]  

  • 25. OUTCOMES AFTER LASER VERSUS COMBINED LASER AND BEVACIZUMAB TREATMENT FOR TYPE 1 RETINOPATHY OF PREMATURITY IN ZONE I.
    Yoon JM; Shin DH; Kim SJ; Ham DI; Kang SW; Chang YS; Park WS
    Retina; 2017 Jan; 37(1):88-96. PubMed ID: 27347645
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment of type I ROP with intravitreal bevacizumab or laser photocoagulation according to retinal zone.
    Mueller B; Salchow DJ; Waffenschmidt E; Joussen AM; Schmalisch G; Czernik C; Bührer C; Schunk KU; Girschick HJ; Winterhalter S
    Br J Ophthalmol; 2017 Mar; 101(3):365-370. PubMed ID: 27301450
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Refractive error outcomes after intravitreal ranibizumab for retinopathy of prematurity.
    Meng Q; Cheng Y; Wu X; Zhao D; Zhao M; Liang J
    Clin Exp Optom; 2020 Jul; 103(4):495-500. PubMed ID: 31802528
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Low-dose ranibizumab as primary treatment of posterior type I retinopathy of prematurity.
    Ells AL; Wesolosky JD; Ingram AD; Mitchell PC; Platt AS
    Can J Ophthalmol; 2017 Oct; 52(5):468-474. PubMed ID: 28985806
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Combine intravitreal bevacizumab injection with laser treatment for aggressive posterior retinopathy of prematurity (AP-ROP).
    Wutthiworawong B; Thitiratsanont U; Saovaprut C; Subhangkasen I; Geyuraphun B; Ampornprut A; Phumongkutchai J; Tephusdinnaayuthaya S
    J Med Assoc Thai; 2011 Aug; 94 Suppl 3():S15-21. PubMed ID: 22043749
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Retinal Detachment after Treatment of Retinopathy of Prematurity with Laser versus Intravitreal Anti-Vascular Endothelial Growth Factor.
    Barry GP; Yu Y; Ying GS; Tomlinson LA; Lajoie J; Fisher M; Binenbaum G;
    Ophthalmology; 2021 Aug; 128(8):1188-1196. PubMed ID: 33387554
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Relationship between refractive outcomes and quantitative retinal vascularization and severity of plus disease in eyes treated with intravitreal bevacizumab.
    Bayramoglu SE; Sayin N
    Indian J Ophthalmol; 2022 Oct; 70(10):3584-3590. PubMed ID: 36190051
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Effects of intravitreal pegaptanib or bevacizumab and laser in treatment of threshold retinopathy of prematurity in zone I and posterior zone II--four years results].
    Autrata R; Senková K; Holousová M; Krejcírová I; Dolezel Z; Borek I
    Cesk Slov Oftalmol; 2012 Feb; 68(1):29-36. PubMed ID: 22679695
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Intravitreal Bevacizumab for Zone II Retinopathy of Prematurity.
    Larrañaga-Fragoso P; Peralta J; Bravo-Ljubetic L; Pastora N; Abelairas-Gómez J
    J Pediatr Ophthalmol Strabismus; 2016 Nov; 53(6):375-382. PubMed ID: 27537247
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Longitudinal Development of Refractive Error in Children Treated With Intravitreal Bevacizumab or Laser for Retinopathy of Prematurity.
    Simmons M; Wang J; Leffler JN; Li S; Morale SE; de la Cruz A; Birch EE
    Transl Vis Sci Technol; 2021 Apr; 10(4):14. PubMed ID: 34003992
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Outcomes of early versus deferred laser after intravitreal ranibizumab in aggressive posterior retinopathy of prematurity.
    Gangwe AB; Agrawal D; Gangrade AK; Parchand SM; Agrawal D; Azad RV
    Indian J Ophthalmol; 2021 Aug; 69(8):2171-2176. PubMed ID: 34304203
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Laser photocoagulation for retinopathy of prematurity: structural and functional outcome.
    Kieselbach GF; Ramharter A; Baldissera I; Kralinger MT
    Acta Ophthalmol Scand; 2006 Feb; 84(1):21-6. PubMed ID: 16445435
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Refractive outcomes following unilateral laser treatment for type 1 retinopathy of prematurity.
    Bayramoglu SE; Sayin N; Ekinci DY
    J AAPOS; 2022 Oct; 26(5):245.e1-245.e6. PubMed ID: 36113701
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Factors associated with refractive outcome in children treated with bevacizumab for retinopathy of prematurity: the importance of retinal vascularization.
    Bayramoglu SE; Sayin N
    Int Ophthalmol; 2022 Oct; 42(10):3199-3210. PubMed ID: 35579771
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combined treatment with laser photocoagulation and cryotherapy for threshold retinopathy of prematurity.
    Autrata R; Senková K; Holousová M; Helmanová I; Pyrochtová S
    Eur J Ophthalmol; 2008; 18(1):112-7. PubMed ID: 18203095
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Does the number of laser applications for ROP treatment influence the degree of myopia?
    Inoue T; Asaoka R; Hashimoto Y; Kitamoto K; Kitano M; Fujita A; Azuma K; Yamamoto K; Nagahara M; Kadonosono K; Obata R
    Graefes Arch Clin Exp Ophthalmol; 2021 Feb; 259(2):317-322. PubMed ID: 32978662
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.